• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now.改善阿片类药物使用障碍的治疗可及性：呼吁立即消除X豁免要求。
Ann Emerg Med. 2021 Aug;78(2):220-222. doi: 10.1016/j.annemergmed.2021.03.023. Epub 2021 May 7.
2
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.支付方在新冠疫情期间确保阿片类药物使用障碍患者获得医疗服务的策略。
Am J Manag Care. 2021 Mar;27(3):91-92. doi: 10.37765/ajmc.2021.88522.
3
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.利用药剂师在 COVID-19 大流行期间维持和扩大阿片类药物使用障碍的丁丙诺啡供应。
Am J Health Syst Pharm. 2021 Mar 18;78(7):613-618. doi: 10.1093/ajhp/zxab003.
4
Eliminating the buprenorphine DEA X waiver is critical to promote health equity.取消丁丙诺啡的美国药品监督管理局（DEA）X类豁免对于促进健康公平至关重要。
Nurs Outlook. 2022 Jan-Feb;70(1):5-7. doi: 10.1016/j.outlook.2021.10.003. Epub 2021 Dec 8.
5
ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.美国医学毒理学学会立场声明：取消开具丁丙诺啡治疗阿片类物质使用障碍的豁免要求。
J Med Toxicol. 2019 Oct;15(4):307-309. doi: 10.1007/s13181-019-00728-9. Epub 2019 Aug 14.
6
Expanding Access to Medications for Opioid Use Disorder: Federal Policy Is Only a Part of the Solution.扩大阿片类药物使用障碍药物的可及性：联邦政策只是解决方案的一部分。
Am J Public Health. 2024 Jul;114(7):693-695. doi: 10.2105/AJPH.2024.307715.
7
A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.一项旨在改善无家可归人群获取丁丙诺啡机会的社区合作项目。
Ann Fam Med. 2021 Jan-Feb;19(1):85. doi: 10.1370/afm.2636.
8
Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths.佛蒙特州伯灵顿市和宾夕法尼亚州费城将被挪用的丁丙诺啡合法化：一项减少阿片类药物过量致死的干预措施。
J Law Med Ethics. 2020 Jun;48(2):373-375. doi: 10.1177/1073110520935353.
9
Revisiting emergency department use of buprenorphine as a primary analgesic in nonopioid use disorder patients post-X-waiver.重新审视急诊科在非阿片类药物使用障碍患者X豁免后将丁丙诺啡用作主要镇痛药的情况。
Acad Emerg Med. 2023 Dec;30(12):1272-1274. doi: 10.1111/acem.14749. Epub 2023 May 30.
10
The Comprehensive Addiction and Recovery Act: Opioid Use Disorder and Midwifery Practice.《综合成瘾与康复法案》：阿片类药物使用障碍与助产实践。
Obstet Gynecol. 2018 Mar;131(3):542-544. doi: 10.1097/AOG.0000000000002493.

引用本文的文献

1
At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead.处于十字路口：阿片类物质使用障碍、X豁免权及未来之路
Ochsner J. 2024 Summer;24(2):108-117. doi: 10.31486/toj.23.0074.
2
The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine.临床决策支持对未放弃开具丁丙诺啡处方的基层医疗临床医生的潜在影响。
Health Aff Sch. 2023 Oct 11;1(4):qxad051. doi: 10.1093/haschl/qxad051. eCollection 2023 Oct.
3
Navigating addiction treatment during COVID-19: policy insights from state health leaders.新冠疫情期间的成瘾治疗导航：来自州卫生领导人的政策见解
Health Aff Sch. 2024 Jan 29;2(2):qxae007. doi: 10.1093/haschl/qxae007. eCollection 2024 Feb.
4
Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care.政策变化对基层医疗中阿片类药物使用障碍药物获取的影响。
South Med J. 2023 Apr;116(4):333-340. doi: 10.14423/SMJ.0000000000001544.
5
Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder.住院医师对阿片类药物使用障碍住院患者丁丙诺啡治疗的看法。
Drug Alcohol Depend Rep. 2022 Oct 9;5:100106. doi: 10.1016/j.dadr.2022.100106. eCollection 2022 Dec.
6
Substance Use Treatment Utilization Among Women With and Without Human Immunodeficiency Virus.感染与未感染人类免疫缺陷病毒的女性的物质使用治疗情况
Open Forum Infect Dis. 2022 Dec 21;10(1):ofac684. doi: 10.1093/ofid/ofac684. eCollection 2023 Jan.
7
Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.丁丙诺啡治疗持续时间、剂量以及苯二氮䓬类药物和阿片类镇痛药的同时处方：医疗补助预授权政策的影响。
Drug Alcohol Depend. 2022 Dec 1;241:109669. doi: 10.1016/j.drugalcdep.2022.109669. Epub 2022 Oct 21.
8
Resident attitudes, experiences, and preferences on initiating buprenorphine in the emergency department: A national survey.住院医师对在急诊科启动丁丙诺啡治疗的态度、经验和偏好：一项全国性调查。
AEM Educ Train. 2022 Jun 29;6(3):e10779. doi: 10.1002/aet2.10779. eCollection 2022 Jun.
9
User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.以患者为中心的临床决策支持在急诊科实施丁丙诺啡治疗阿片类药物使用障碍：EMBED 实用集群随机对照试验。
BMJ. 2022 Jun 27;377:e069271. doi: 10.1136/bmj-2021-069271.
10
How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis.如何解决医师劳动力短缺问题，以应对阿片类药物危机。
Psychiatr Serv. 2022 May;73(5):547-554. doi: 10.1176/appi.ps.202000565. Epub 2021 Sep 15.

本文引用的文献

1
Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?消除阿片类药物使用障碍治疗的一个障碍：这足够了吗？
JAMA. 2021 Mar 23;325(12):1147-1148. doi: 10.1001/jama.2021.0958.
2
Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients.商业保险患者非致死性药物过量后治疗阿片类药物使用障碍的发生率。
JAMA Netw Open. 2020 May 1;3(5):e205852. doi: 10.1001/jamanetworkopen.2020.5852.
3
Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.临床医生准备在急诊科提供丁丙诺啡的障碍和促进因素。
JAMA Netw Open. 2020 May 1;3(5):e204561. doi: 10.1001/jamanetworkopen.2020.4561.
4
Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder.以患者为中心的临床决策支持在急诊科应用丁丙诺啡治疗阿片类药物使用障碍的中断时间序列研究。
Acad Emerg Med. 2020 Aug;27(8):753-763. doi: 10.1111/acem.14002. Epub 2020 May 19.
5
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.丁丙诺啡在美国：滥用、误用和转移的动机。
J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Epub 2019 Jul 12.
6
The Opioid Crisis in Black Communities.黑人社群的阿片类药物危机。
J Law Med Ethics. 2018 Jun;46(2):404-421. doi: 10.1177/1073110518782949.
7
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.非致死性阿片类药物过量后治疗阿片类药物使用障碍的药物与死亡率的关系：一项队列研究。
Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19.
8
Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.急诊科启动的丁丙诺啡/纳洛酮治疗阿片类药物依赖：一项随机临床试验。
JAMA. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474.
9
A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.丁丙诺啡转移与滥用综述：当前的证据基础及全球经验
J Addict Med. 2014 Sep-Oct;8(5):315-26. doi: 10.1097/ADM.0000000000000045.
10
French field experience with buprenorphine.法国丁丙诺啡的实地经验。
Am J Addict. 2004;13 Suppl 1:S17-28. doi: 10.1080/10550490490440780.

Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now.

作者信息

D'Onofrio Gail, Melnick Edward R, Hawk Kathryn F

机构信息

Department of Emergency Medicine, Yale School of Medicine, New Haven, CT.

Department of Emergency Medicine, Yale School of Medicine, New Haven, CT.

出版信息

Ann Emerg Med. 2021 Aug;78(2):220-222. doi: 10.1016/j.annemergmed.2021.03.023. Epub 2021 May 7.

DOI:10.1016/j.annemergmed.2021.03.023
PMID:33966933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8324519/
Abstract
摘要